KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting ...
The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...
Title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi Date/time: Monday, ...
1d
Lyme disease often goes undetected when it's most treatable. These teens are working to change that.
Teens at a Georgia high school may have come up with a better way to detect and treat Lyme disease. They took their idea to ...
To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...
But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...
Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some ...
Key breakthrough for the return of the dodo: viable cells have been obtained and genetically modified birds have been prepared.
CRISPR-based gene editing has revolutionized modern biology, but these tools are unable to access the DNA that resides inside ...
As reported in the Wall Street Journal, Armstrong has now officially entered the designer-baby business by funding heritable ...
Highlighting 10 innovative late-stage BioPharma drugs with the potential to reshape treatment paradigms and industry dynamics ...
Find out how understanding the genetic basis of heart defects can lead to better outcomes for children with congenital heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback